万古霉素治疗老年耐甲氧西林金黄色葡萄球菌肺炎的临床药学研究  

Clinical pharmacy research of vancomycin in the treatment of methicillin-resistant Staphylococcus aureus pneumonia in the elderly

作　　者：王兴征[1] WANG Xing-zheng(Department of Pharmacy,Jiaxiang County People’s Hospital,Jining 272400,China)

机构地区：[1]山东嘉祥县人民医院药剂科,272400

出　　处：《中国现代药物应用》2020年第11期109-111,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨分析万古霉素治疗老年耐甲氧西林金黄色葡萄球菌(MRSA)肺炎的临床疗效及安全性。方法50例老年MRSA肺炎患者,根据治疗方案不同分为观察组和对照组,每组25例。两组均予以常规治疗,在此基础上,观察组采用万古霉素静脉滴注治疗,对照组采用利奈唑胺静脉滴注治疗。对比两组临床疗效、MRSA清除率、用药时间、治疗总费用及不良反应发生情况。结果观察组临床总有效率为76.0%,与对照组的84.0%比较,差异无统计学意义(P>0.05)。观察组MRSA清除率为80.0%,与对照组的84.0%比较差异无统计学意义(P>0.05)。两组用药时间比较差异无统计学意义(P>0.05);观察组治疗总费用(1653.12±150.57)元显著少于对照组的(5436.96±381.56)元,差异具有统计学意义(P<0.05)。观察组不良反应发生率8.0%与对照组的4.0%对比,差异无统计学意义(P>0.05)。结论万古霉素治疗老年MRSA肺炎的疗效与新型替代药物利奈唑胺相当,不良反应较少,且其在价格上更具优势,更适宜基层医院推广应用。Objective To discuss and analyze the clinical efficacy and safety of vancomycin in the treatment of methicillin-resistant Staphylococcus aureus(MRSA)pneumonia in the elderly.Methods A total of 50 elderly patients with MRSA pneumonia were divided into observation group and control group by different treatment regimens,with 25 cases in each group.Both groups received conventional therapy,and the observation group also treated by intravenous infusion of vancomycin,and the control group also received intravenous infusion of linezolid.The clinical efficacy,clearance rate of MRSA,time of medication,total cost of treatment and occurrence of adverse reactions were compared between the two groups.Results The total clinical effective rate of the observation group was 76.0%,which had no statistically significant difference compared with that of the control group 84.0%(P>0.05).The clearance rate of MRSA of the observation group was 80.0%,which had no statistically significant difference compared with that of the control group 84.0%(P>0.05).There was no statistically significant difference in time of medication between the two groups(P>0.05).The total cost of treatment(1653.12±150.57)yuan of the observation group was significantly less than that of the control group(5436.96±381.56)yuan,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 8.0%of the observation group had no statistically significant compared with that of the control group 4.0%(P>0.05).Conclusion Vancomycin has the same efficacy as linezolid in the treatment of elderly MRSA pneumonia,with less adverse reactions,and it has more advantages in price,which is more suitable for the promotion and application in basic hospitals.

关 键 词：耐甲氧西林金黄色葡萄球菌肺炎 万古霉素 老年 临床疗效 安全性 

分 类 号：R563.1[医药卫生—呼吸系统]